Across TCGA pan-cancer cohorts, AP3M1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AP3M1 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher AP3M1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP3M1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, UCEC, and LUAD are the cancer types where AP3M1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.157	0.867	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.614	.012	12	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: AP3M1 tumor-vs-normal RNA expression · all AP3M1 data types